ClinicalTrials.gg
CompletedNCT01074138Updated Feb 2, 2023

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

A Phase 2 interventional study of KX2-391 in Bone-Metastatic, Castration-Resistant Prostate Cancer, sponsored by Athenex, Inc.. Completed at 5 sites in United States. Open to male participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Athenex, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
1,878th of 3,023
31 · median 48
Started
2010
with 104 others
Phase 2
1,063 of 3,596
145 open now
Registered
1,066th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,878th largest by enrollment of the 3,023 interventional ones that give a count, is one of 105 that started in 2010, is one of 1,063 in phase 2, and was the 1,066th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 85 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The standard of care for patients with bone-metastatic, castrate-resistant prostate cancer is chemotherapy. If a patient elects not to choose chemotherapy, 70% will progress within 6 months. KX2-391 given orally twice a day for 6 months will be evaluated for its ability to delay/prevent disease progression in patients who have not had prior chemotherapy.

Read the detailed description

This is a multi-center, single-arm, open-label, prospective phase II clinical trial evaluating the efficacy, safety and pharmacokinetics of orally administered KX2-391 in adult male patients with progressive bone-metastatic CRPC. Patients must have 1) documented bone-metastatic prostate cancer, 2) castrate levels of testosterone, 3) not received prior chemotherapy, and 4) documented disease progression based on rising PSA, progressive measurable visceral disease and/or progressive bone lesions (one criteria is sufficient) as per the Prostate Cancer Clinical Trials Working Group (PCWG2) guidelines (Scher et al 2008).

03

Conditions studied

  • Bone-Metastatic, Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • CPRC
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must provide signed prior to performing any study-related procedures;
  • The patient must have or cytologically confirmed prostate adenocarcinoma;
  • The patient must have presence of at least one documented osseous on bone scan;
  • The patient must have a castrate testosterone level \<50ng/dl within 4 weeks prior to initiation of KX2-391 treatment. If chemically castrate, the patient must also agree to stay on luteinizing hormone releasing hormone (LHRH) agonist medication for the duration of the study;
  • The patient must have documented disease progression as evidenced by one or more of the following 3 criteria:
  • Rising PSA, defined as three rising PSA values ≥ 2 weeks apart with the 3rd value 2ng/ml or greater (historical values may be used). Rising PSA must be seen in the 3rd value relative to the 2nd value AND in the 2nd value relative to the 1st value (i.e. two consecutive rises over time muse be noted). Given potential for fluctuations in PSA values, one drop in rising PSA values over time may be seen when determining eligibility. Pre-therapy PSA doubling time may also be calculated (if there are 3 or more values 4 or more weeks apart.
  • Evidence of nodal or visceral progression. Progression must be evident within 3 months prior to study entry.
  • Radiographic documentation of disease is required by CT (or MRI, when CT is not available)(using 1.1 criteria) within 4 weeks of study entry.The patient must have at least 1 unidimensionally ≥ 20mm by conventional techniques (i.e., conventional CT or chest x-ray) OR ≥ 10mm by spiral CT scan.Only lymph nodes ≥ 20mm in diameter may be counted.CT is preferred over MRI. The radiographic measurement technique used at Baseline must be serially used throughout the duration of the study.
  • Evidence of progression of bone metastases on bone scan. Appearance of ≥ 2 new lesions since the prior scan (prior scan obtained within 3 months of study entry).Documentation of bone metastases by bone scintigraphy (using PCWG2 criteria) within 4 weeks of study entry.
  • The patient must have no known (confirmation by CT and/or MRI is not required);
  • The patient be a ≥ 18 year old male at the time of enrollment;
  • The patient must have an (ECOG) performance status score of ≤ 2;
  • The patient must have an estimated of ≥ 6 months;
  • The patient must have adequate hematopoietic function as demonstrated by 1) of ≥ 9.0g/dL, 2) count ≥ 100,000ul, 3) WBC count ≥ x109/L, and 4) ≥ 1.5 x109/L;
  • The patient must have adequate hepatobiliary function as demonstrated by 1) a level ≤ 1.5 times the (ULN), unless the patient has Gilbert's syndrome in which case he/she must have a bilirubin level ≤ 2.5 times the upper limit of normal and 2) (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times the ULN;
  • The patient must have adequate renal function as demonstrated by a creatinine level ≤ 1.5 times the ULN and a (measured or calculated) ≥ 35 mL/min;
  • Patients with partners of must be willing to abstain from sexual activity or practice physical barrier during study participation and for at least 3 months after completion of KX2-391 treatment;
  • The patient must be able to self-administer KX2-391 and agree to adhere to the study visit schedule; study treatment schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • The patient has had other prior (with the exception of basal cell or squamous cell carcinoma of the skin and superficial transitional cell carcinoma of the bladder) within 3 years of study entry;
  • The patient has a history of major cardiovascular or neurologic disease within the 6 months prior to enrollment, including, but not limited to, uncontrolled hypertension (at the discretion of the Investigator)\< Class III or IV congestive heart failure, myocardial infarction, confirmed significant cardiac conduction abnormalities (including > 0.45 sec) or arrhythmias, cerebrovascular accident(s), (s), peripheral artery disease (i.e., claudication on walking less than one block), or other major arterial thrombotic events (e.g., pulmonary embolism) (Note: Patients with deep venous thrombosis are eligible for inclusion if they have been on a stable dose of anticoagulation therapy for at least 4 weeks prior to study entry;
  • The patient has peripheral neuropathy ≥ grade 2 as defined using (CTCAE);
  • The patient has uncontrolled diabetes mellitus in the opinion of the Investigator;
  • The patient has experienced hemoptysis or significant bleeding episode within 6 months prior to enrollment;
  • The patient has had upper or lower gastrointestinal (GI) bleeding within 6 months prior to enrollment;
  • The patient has had a GI perforation within 12 months prior to enrollment;
  • The patient has had major surgery of the GI tract or a history of inflammatory bowel disease, malabsorption syndrome or other medical condition that would interfere with oral drug absorption;
  • The patient has a serious or non-healing wound or ulcer;
  • The patient has a known history of pathological bone fracture;
  • The patient has a known history of , C, or (HIV) infection;
  • The patient received moderate or strong CYP450 3A4 modulators (inducers or inhibitors) within 2 weeks or 5 half-lives (whichever is shorter) prior to initiation of KX2-391 dosing and during the study;
  • The patient received prior treatment with estramustine or suramin;
  • The patient received treatment with flutamide, bicalutamide, nilutamide, or ketoconazole within 4 weeks of study entry;
  • The patient received prior chemotherapy for prostate cancer;
  • The patient received 5α-reductase inhibitors (e.g., finasteride, dutasteride) within 4 weeks of study entry;
  • The patient received other hormonal therapy [e.g., aminoglutethimide, megestrol, diethylstilbestrol (DES)] within 6 weeks of study entry;
  • The patient is on other concurrent endocrine therapy, the exception of 1) for adrenal insufficiency or disease, if on a stable dose for > 3 months, 2) intermittent dexamethasone as an antiemetic (to be avoided, if at all possible); and 3) hormones for non-disease-related illnesses (e.g. insulin for diabetes);
  • The patient received strontium chloride (Sr89) or samarium (Sm153) lexidronam pentasodium therapy within 12 weeks of study entry;
  • The patient received extensive radiation therapy (including sternum, pelvis, scapulae, vertebrae or skull) within 4 weeks of study entry;
  • The patient received extensive radiation therapy > 4 weeks before study entry and has not recovered from side effects of therapy;
  • The patient received palliative low dose radiation therapy limited to the limbs within 2 weeks of initiating KX2-391;
  • The patient is on bisphosphonates and the dose has changed in the 4 weeks prior to study entry (initiation of bisphosphonates during the study is not permitted);
  • The patient is receiving full-dose anticoagulation therapy and dose has been modified in the 4 weeks prior to study entry (patients on low molecular weight heparin or aspirin are eligible for study enrollment);
  • PT or is > 1.5 times the and the patient is not on any anti-coagulation therapy or anti- agents;
  • The patient is expected to initiate chemotherapy or palliative radiotherapy while on the study;
  • The patient is either currently receiving or is expected to receive treatment with filgrastim (G-CSF), pegfilgrastim, or sargramostim (GM-CSF) during the study period (these medications and therapies may only be initiated when clinically indicated during the study);
  • The patient has had major surgery within 4 weeks of study entry;
  • The patient has had major surgery within > 4 weeks prior to study entry and has not fully recovered from the surgery;
  • The patient received other agents/therapies within 28 days of study entry;
  • The patient has persistent ≥ grade 2 treatment-related toxicity from prior anti-cancer therapy, including other investigational agents;
  • The patient has any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study, including, but not limited to, end organ failure, coagulation disorder, hemolytic condition (e.g. sickle cell disease) or active infection;
  • The patient has any other condition(s) which could significantly interfere with protocol compliance, including, but not limited to, dementia, psychosis, cognitive impairment, or other major psychiatric disorder;
  • The patient has previously participated in the Phase I clinical trial of KX2-391.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Treatment

    Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.

    Drug: KX2-391

Interventions

  • KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.

    Also known as: KXO1

06

What researchers measure

Primary outcomes

  1. The proportion of patients who do not have clinical or radiographic progression

    At screening/baseline, target lesions will be identified and measured by CT scan and bone lesions will be enumerated by bone scintigraphy. At 12 and 24 weeks after treatment with KX2-391, patients will be assessed by CT and bone scan to assess whether radiographic progression has occurred. At monthly visits and throughout the study, clinical progression will be evaluated.

    Time frame: 24 weeks

Secondary outcomes

  1. Determine the proportion of patients who do not have PSA progression

    PSA will be measure at baseline and at the start of each of 6, 28 day cycles

    Time frame: 24 weeks

  2. Determine the pharmacokinetics of KX2-391

    Pharmacokinetic parameters will be determined in patients receiving 40 mg KX2-391, twice daily.

    Time frame: 24 weeks

07

Study locations

5 sites
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Wayne State University-Karmanos Cancer Center
    Detroit, Michigan 48201, United States
  • University of Washington
    Seattle, Washington 98109, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
08

References and documents

Publications

  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. PubMed 18309951 ↗
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PubMed 19097774 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Jun 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2010
First posted
Feb 24, 2010
Start
Feb 2010
Primary completionActual
Jun 2012
CompletionActual
Oct 2012
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01074138
Lead sponsor
Athenex, Inc.
Responsible party
Sponsor
First posted
Feb 24, 2010
Start date
Feb 2010
Primary completion
Jun 2012
Completion
Oct 2012
Last update
Feb 2, 2023

Study contacts

Michael Carducci, MD
principal investigator · Johns Hopkins University
Min-Fun Rudolf Kwan, MD
study director · Kinex Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion